Blue Earth Therapeutics
UK - OxfordPharmaceutical
Focus: Blue Earth Therapeutics is a UK-based radiopharmaceutical company specializing in PET imaging and targeted radiotherapy for oncology and neurology indications. The company is at Series A stage with a portfolio focused on fluorine-18 and actinium-225 based diagnostics and therapeutics.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES A
Open Jobs
0
About Blue Earth Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Blue Earth Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
8 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Fluciclovine
Prostatic NeoplasmsClinical Trials (2)
NCT07569926Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Phase 4Help build intelligence for Blue Earth Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.